Xiaojun Wang

Xiaojun Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
HYHongqiang Yu
Hongqiang Yu
YZYujun Zhang
Yujun Zhang
LSLing Shuai
Ling Shuai
CPCong Peng
Cong Peng
CZChangchun Zhao
Changchun Zhao
XWXiaojun Wang
Xiaojun Wang
Rationale: Biliary complications after liver transplantation persistently affect patient prognosis and graft survival. Neutrophil-mediated immune injury is an important factor leading to biliary injury. However, the mechanism by which neutrophils reach the periphery of the bile duct and further mediate bile duct injury is not fully understood.

6 May 2025 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
KLKe-Xi Liao
Ke-Xi Liao
LCLi Cao
Li Cao
RGRui Guo
Rui Guo
BWBao-Lin Wang
Bao-Lin Wang
JWJin-Ao Wang
Jin-Ao Wang
XWXiaojun Wang
Xiaojun Wang

9 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
KLKe Li
Ke Li
RGRui Guo
Rui Guo
JLJing Li
Jing Li
QWQian Wu
Qian Wu
XLXiaoling Liu
Xiaoling Liu
WCWei Chen
Wei Chen
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with poor prognosis, where SMAD4 protein loss is closely associated with increased tumor aggressiveness and metastatic potential. Current assessment of SMAD4 expression relies on IHC of tumor tissue obtained by biopsy or resection, in which limited sampling may not represent intratumoral heterogeneity. T1ρ-weighted imaging, an emerging functional MRI technique, shows promise in characterizing tumor microstructural properties. This study aimed to evaluate the value of T1ρ imaging combined with conventional MRI sequences and clinical parameters for non-invasive prediction of SMAD4 protein expression status in PDAC. Methods: This retrospective single-center study included 57 patients with histologically confirmed PDAC who underwent pretreatment MRI with T1ρ imaging between September 2024 and May 2025. Immunohistochemical analysis revealed SMAD4 intact in 28 tumors (49.1%) and SMAD4 loss in 29 tumors (50.9%). T1ρ values were measured and compared between SMAD4 intact and SMAD4 loss tumors. A multiparametric predictive model incorporating T1ρ values, lymph node metastasis status, and carbohydrate antigen 19-9 (CA19-9) levels was developed. Results: SMAD4 intact tumors demonstrated significantly higher T1ρ values compared to SMAD4 loss tumors (96.34 ± 14.12 vs. 71.93 ± 10.24 ms, p < 0.001). T1ρ achieved an AUC of 0.901 (95% CI: 0.817–0.986), with 82.14% sensitivity and 89.66% specificity, for predicting SMAD4 expression status. A multiparametric model combining T1ρ values, lymph node metastasis status, and CA19-9 levels yielded a numerically higher AUC of 0.932 (95% CI: 0.862–1.000), although the difference from T1ρ alone was not statistically significant (DeLong test, p > 0.05). Conclusions: T1ρ imaging showed potential for predicting SMAD4 status in PDAC.